What Role Is There for Patients In Managed Access Deals?

Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.  

Question marks
• Source: Shutterstock

England has a long history of deals that have secured patient access to new treatments, going back to the first agreement on Jansen Cilag’s Velcade (bortezomib) in 2007. There are more than 400 commercial arrangements now, according to an Excel spreadsheet from NICE, the cost-effectiveness watchdog for England and Wales.

England allows for a range of deals, from simple discounts to more sophisticated arrangements where access hinges not only on...

More from Market Access

More from In Vivo